---
title: "CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team"
description: "- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255617485.md"
published_at: "2025-09-02T12:09:09.000Z"
---

# CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

> - Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential -

\- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential -

### Related Stocks

- [CRMD.US - Cormedix](https://longbridge.com/en/quote/CRMD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CorMedix Investor Day: Melinta Deal Fuels Shift to Multi-Product Pharma, Rezzayo Q2 Data Ahead | CorMedix (NASDAQ:CRMD) announced a strategic shift from a single-product renal company to a diversified specialty pharma | [Link](https://longbridge.com/en/news/275523726.md) |
| CorMedix Inc. (CRMD) board approves multi-year $75M stock buyback | CorMedix Inc. (NASDAQ:CRMD) has announced a share repurchase program approved by its board, allowing for up to $75 milli | [Link](https://longbridge.com/en/news/275654068.md) |
| Analyst Expectations For Cormedix's Future | In the past three months, six analysts have rated Cormedix (NASDAQ:CRMD), showing a mix of bullish to bearish sentiments | [Link](https://longbridge.com/en/news/275609296.md) |
| CorMedix Announces $75 Mln Share Buyback Program | CorMedix Therapeutics (CRMD) has announced a share repurchase program of up to $75 million, approved by its Board, to be | [Link](https://longbridge.com/en/news/274523823.md) |
| CorMedix Hosts Analyst Day to Showcase Pipeline and Growth Drivers | CorMedix Inc. will host an analyst day on February 10, 2026, in New York, featuring presentations from key opinion leade | [Link](https://longbridge.com/en/news/274158609.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.